Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Trump signs order aimed at development of better flu vaccines

U.S. President Donald Trump signed an executive order aimed at spurring the development of better vaccines to protect against seasonal influenza as well as a potential pandemic flu outbreak.

Read More »

Researchers Develop New Class of Lung Cancer Drugs

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.

Read More »

Biogen Halts Mid-Stage IPF Drug Trial

Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Read More »

Novartis reports positive data in Cosentyx study

Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.

Read More »

Prostate drug may be useful for Parkinson’s disease

Collaborating researchers at the University of Iowa and Capital Medical University in China found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.

Read More »

Biogen scraps late-stage trials for Alzheimer’s drug

Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.

Read More »

Are Drugmakers Going After the Right Targets in Cancer Cells?

Researchers from Cold Spring Harbor Laboratory in New York discovered that certain proteins believed essential for the survival of cancer cells – the same proteins that many drugmakers have been targeting – may not be as important after all.

Read More »

Genentech’s Satralizumab Shows Strong Results in Rare CNS Disorder

Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.

Read More »

Tocagen’s brain cancer treatment fails late-stage study

Tocagen Inc.’s shares fell nearly 80 percent after the company’s experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.

Read More »

Bristol-Myers Squibb’s Opdivo Shows 5-Year Survival Benefit in Lung Cancer

Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom